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Abstract
Background—Inflammation is the most prevalent and widespread histological finding in the 
human prostate, and associates with the development and progression of benign prostatic 
hyperplasia and prostate cancer. Several factors have been hypothesized to cause inflammation, yet 
the role each may play in the etiology of prostatic inflammation remains unclear. This study 
examined the possibility that the common protozoan parasite Toxoplasma gondii induces prostatic 
inflammation and reactive hyperplasia in a mouse model.
Methods—Male mice were infected systemically with T. gondii parasites and prostatic 
inflammation was scored based on severity and focality of infiltrating leukocytes and epithelial 
hyperplasia. We characterized inflammatory cells with flow cytometry and the resulting epithelial 
proliferation with bromodeoxyuridine (BrdU) incorporation.
Results—We found that T. gondii infects the mouse prostate within the first 14 days of infection 
and can establish parasite cysts that persist for at least 60 days. T. gondii infection induces a 
substantial and chronic inflammatory reaction in the mouse prostate characterized by monocytic 
and lymphocytic inflammatory infiltrate. T. gondii-induced inflammation results in reactive 
hyperplasia, involving basal and luminal epithelial proliferation, and the exhibition of proliferative 
inflammatory microglandular hyperplasia in inflamed mouse prostates.
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Conclusions—This study identifies the common parasite T. gondii as a new trigger of prostatic 
inflammation, which we used to develop a novel mouse model of prostatic inflammation. This is 
the first report that T. gondii chronically encysts and induces chronic inflammation within the 
prostate of any species. Furthermore, T. gondii-induced prostatic inflammation persists and 
progresses without genetic manipulation in mice, offering a powerful new mouse model for the 
study of chronic prostatic inflammation and microglandular hyperplasia.
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1 INTRODUCTION
Prostate cancer and benign prostatic hyperplasia (BPH) are both very common and costly 
urological conditions in aging men. Prostatic carcinomas exist in up to 29% of men 30–40 
years of age, and are found in 64% of men in their sixties.1 The risk of death due to 
metastatic prostate cancer is now up to 1 in 30 in western countries.2 Similarly, benign 
prostatic growth is a nearly ubiquitous process in aging men and is characterized by 
proliferation of epithelium and stroma in the periurethral and transition zones of the prostate. 
Nearly every man, regardless of race or ethnicity, will develop BPH and experience 
inconvenient, painful, and sometimes intolerable lower urinary tract symptoms, which range 
from hesitancy and weak stream to increased urgency and increased frequency, especially at 
night. No single causative factor has been identified for BPH or prostate cancer, though 
numerous factors have been proposed, including diet, endocrine signaling from androgens or 
estrogens, genetic susceptibilities, and exposure to environmental carcinogens. However, one 
pathological feature is dominant in proliferative prostatic diseases: continual and recalcitrant 
inflammation.3
Inflammation of the human prostate is a critical area of urological research due to its 
common concurrence with prostate cancer and BPH.4–6 Prostatic inflammation is diagnosed 
histologically from the presence of inflammatory cells infiltrating the prostatic stroma, 
epithelium, and lumen of prostate glands.7 In the transitional zone of the human prostate, the 
cellular nature inflammation is primarily lymphocytic with secondary accompanying 
macrophages juxtaposed to loci of reactive hyperplasia.8 Additionally, inflammation in the 
prostate associates with dysplastic changes including focal disruption of the epithelium, 
polymorphisms of epithelial cell nuclei, and increased epithelial proliferation, and 
proliferative atrophy.2,3
Human prostatectomy specimens exhibit proliferating epithelial cells and activated 
inflammatory cells juxtaposed to neoplasia and hyperplastic glands. Numerous prostate 
disease susceptibility genes function in the inflammatory response.4,5 Sustained cell 
proliferation in an environment rich in inflammatory cells, growth factors, and reactive 
stroma, potentiate prostatic epithelial growth.9 Interleukins 1 and 6, tumor necrosis factor, 
and prostanoids all promote tumor cell growth in culture, and all are increased in both BPH 
and prostate cancer specimens relative to controls.10–12 In addition, prostatic inflammation 
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is associated with more severe symptoms and an increased risk for clinical progression of 
BPH,13 as there is a clear correlation of inflammation with BPH symptom severity.14
The origins of inflammation in the prostate are likely multi-factorial and may include 
bacterial colonization by culturable or non-culturable organisms,15,16 viruses, 
environmental, and dietary components, systemic androgen and estrogens, associations with 
metabolic syndrome, and urinary reflux of any of these noxious stimuli into the prostatic 
ducts.17 However, the role each may play in the etiology of human prostatic inflammation 
still remains unclear.
Toxoplasmosis and various pathologies correlated with chronic toxoplasmosis, such as 
systemic lupus erythematosus18 and inflammatory bowel disease,19 have an inflammatory 
component.18–25 Toxoplasmosis is caused by the common parasite, Toxoplasma gondii, an 
obligate intracellular protozoan capable of infecting any nucleated mammalian or avian cell.
26
 Serology testing has confirmed that almost 1/3 of the western population has been 
exposed to T. gondii, with certain populations showing an infection rate as high as 80%.27,28 
Humans can become infected through multiple routes, including the ingestion of oocysts 
deposited into the environment by felines (the definitive host) in their feces, ingestion of 
tissue cysts in the raw or undercooked meat of infected animals, and congenital transmission 
across the placenta. Upon initial infection, immune competent individuals may experience 
mild flu-like symptoms as the immune response prompts the rapidly replicating form of the 
parasite (tachyzoite) to convert into a latent tissue cyst form (bradyzoite). Bradyzoite tissue 
cysts, which can be found at high frequency in the brain and muscular tissue, allow T. gondii 
to persist as a lifelong chronic infection in the host.29,30 Impervious to current drug 
treatments, the tissue cysts are not eradicated from the host and can reactivate into the 
proliferative form if immunity becomes compromised. Since the latent cyst stage of T. 
gondii had not been associated with symptomology or pathogenesis in the 
immunocompetent, little attention has been given to its presence in specific infected organs. 
In this report, we show for the first time that T. gondii promotes prostatic inflammation and 
the subsequent reactive hyperplasia in mice. Furthermore, we present a comprehensive 
characterization of a murine model of chronic prostatic inflammation, one which persists 
and progresses in severity without genetic manipulation.
2 MATERIALS AND METHODS
2.1 Parasites strains and culture
T. gondii parasites of strain PruΔhxprt + ldh2GFP (aka PruΔC32)31 were grown on human 
foreskin fibroblasts (HFF) obtained from ATCC. HFFs were maintained in Dulbecco’s 
medium supplemented with 10% heat-inactivated fetal bovine serum (FBS), 2 mM L-
glutamine, 100 U/mL penicillin, and 100 µg/mL streptomycin in a humidified incubator at 
37°C with 5% CO2.
2.2 Animal infections
All mice used in this study were housed at the Indiana University School of Medicine under 
approval and supervision of the Animal Care and Use Committee of the Indiana University 
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School of Medicine in accordance with the National Institutes of Health Guide for the Care 
and Use of Laboratory Animals. Tachyzoites were isolated from host cells immediately prior 
to infection by scraping host cell monolayers, passing through a 27.5 gauge syringe three 
times, and filtering through a 3 µm pore filter. A 6–8-week-old male CBA/J mice were 
intraperitoneally injected with either sterile PBS as vehicle control or 40 000 PruΔC32 
tachyzoites. Control or experimental groups were randomized to sacrifice and process at 
either 14, 28, or 60 days post infection. Mice were intraperitoneally injected 2 h prior to 
sacrifice with 250 µL of 3.1 mg/mL bromodeoxyuridine. Infection was verified by testing 
mouse sera in immunoblotting assays.
2.3 Tissue harvesting and processing
Freshly harvested prostates were dissected into individual ventral, dorsal lateral, and anterior 
lobes then bilaterally cut in two. One lobe of each region was fixed in 10% neutral buffered 
formalin for at least 24 h. The other portions were flash frozen in liquid nitrogen then stored 
in −80°C for protein extraction. Fixed tissues were processed via dehydration through 
graded ethanol and xylene, then embedded into paraffin blocks. Five micrometre sections 
were cut by microtome then heat fixed to glass slides.
2.4 Immunofluorescence
Heat fixed paraffin embedded sections were prepared for immunohistochemical analysis as 
previously described.32 Slides were incubated overnight at 4°C with one or a combination of 
the following, diluted in blocking buffer (10% normal donkey serum, 1% bovine serum 
albumin in PBS-T): mouse anti-GFP (CAT#: am10009a, Abgent) at 1:50, rabbit anti-pan-
cytokeratin at 1:50 (Novus, NBP2-29429), rhodamine-labeled Dolichos biflorus agglutinin 
at 1:350 (CAT #: RL-1032, Vector Labs), rabbit anti-BAG1 at 1:100 (provided by Dr Laura 
Knoll),33 mouse anti-CD45 (CAT#: 136-4B5, Cell Signaling) at 1:100, mouse anti-CD3ε 
(CAT#: MA1-7630, Thermo) at 1:100, rat anti-F4-80 (CAT#: MA1-91124, Thermo), mouse 
anti-CD20 (CAT#: MA1-7634, Thermo), mouse anti-Bromodeoxyuridine at 1:200 (CAT#: 
5292, Cell Signaling), rabbit anti-Keratin 5 at 1:1000 (CAT#: PRB-160P, Covance), or 
mouse anti-cytokeratin 8 (CAT#: NB120-9287, Novus). After sections had been washed 
with PBS-T, Invitrogen Alexa Fluor 488 or 594 anti-mouse, rabbit, or rat IgG secondary 
antibodies at 1:200 were applied for 1 h at room temperature in the dark. After serial washes 
with PBS-T, sections were incubated with 20 µg/mL Hoechst 33342 in PBS-T for 10 min to 
visualize nuclei. Coverslips were mounted using PermaFluor Mountant media (CAT#: 
TA-030-FM, Thermo). Slides were viewed using a Nikon Eclipse E100080i microscope and 
digital images were captured with Hamamatsu C4742-95 charge-coupled device camera 
using NIS elements software.
2.5 Inflammatory scoring
Tissue sections were stained with hematoxylin and eosin and viewed on a Leica DM 2500 
microscope. Three random 10× images/mouse were taken using a Leica 2500 microscope 
and DCF425C Camera and analyzed with LASX software. Inflammatory response of the 
DLP, AP, and VP were scored in a blinded manner and graded based on severity and focality 
of inflammatory infiltrate and epithelial hyperplasia as previously described.34
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2.6 Protein extraction
Flash frozen prostate tissues were placed into 1.5 mL screw cap tubes with 500 µL ice-cold 
lysis buffer (0.12 g Tris base, 0.9g NaCl in 100 mL of ddH20, pH to 8.0, Halt Protease/
Phosphatase Inhibitor Cocktail: 1:100) (CAT#: 78446, Thermo) and minced into ~1 mm 
pieces. Prostates were homogenized using a Power Gen 125 on ice for no longer than 5 min. 
A total of 1% v/v of Triton-X was added to each vial and slurries were incubated on ice for 
one hour with periodic vortexing. Vials were then centrifuged at 14 500 rpm for 10 min. The 
supernatant was removed and stored in −80°C until use.
2.7 Western blotting
Protein concentrations were quantified by bicinchoninic acid colorimetric assay. 
Absorbances were determined using a BioTek Synergy HI hybrid reader and Gen5 2.0 
software. Equal amounts of proteins were resolved by SDS-PAGE and transferred to 
nitrocellulose membranes. To prevent nonspecific binding, membranes were incubated in 
blocking buffer (5% milk, 5% BSA, in PBS-T) overnight at 4°C. Membranes were incubated 
with mouse anti-GFP at 1:2000 (CAT#: AM1009A, Abgent) and mouse anti-β-actin at 
1:2000 as a loading control (CAT#: 3700, Cell signaling), diluted in 5% BSA and PBS-T 
overnight at 4°C. Membranes were washed and then incubated with anti-mouse IgG 
horseradish peroxidase linked secondary antibody at 1:5000 (CAT#: 7076S, Cell Signaling) 
in 5% Milk 2% BSA in PBS-T. For visualization, membranes were treated with Super Signal 
West Femto and Pico Chemiluminescent Substrate (CAT# 34095, 34078, Thermo) 
developing reagents at 1:10 and allowed to incubate for 5 min. Developed GFP blots were 
exposed to films for 5 min and Actin blots were exposed for 1 min before processing.
2.8 Flow cytometry
Mouse prostates were processed into single-cell suspensions and intracellular and 
extracellular markers of interest were labeled as previously described.35 Before applying 
primary antibodies to the cells, non-specific Fc Receptor binding was blocked using 0.5 µg/
million cells of purified functional grade anti-mouse CD16/CD32 (CAT#: 16-0161, 
eBioscience) diluted in 100 µL of PBS, and incubated on ice for 30 min. After surface 
staining, cells were fixed using Cytofix/Cytoperm Fixation and Permeabilization Solution 
(CAT#: 554722, BD Bioscience) either overnight at 4°C (surface staining experiments) or 
(intracellular staining) at room temperature for 30 min. After staining, cells were 
resuspended in Cytofix/Cytoperm Fixation and Permeabilization Solution and transferred 
into a sterile 5 mL Polystyrene round-bottom tube with cell strainer cap (CAT#: 352235, 
Falcon) and stored overnight at 4°C. Analysis was carried out at the Indiana University 
Simon Cancer Center Flow Cytometry Research Core Facility on a BD Biosciences 
FACSAria. Analysis was performed using FloJo Software.
Single-color compensation controls for each experiment were prepared using UltraComp 
eBeads (CAT#: 00-4222, eBioscience). Autofluorescence was controlled for using unstained 
cells and fluorochrome conjugated isotype antibodies.
T-cell and dendritic cell analysis was performed using antibodies at the following 
concentrations: 0.5 µg/million cells rat IgG2b Κ, mouse anti-CD45 eFluor 450 (CAT#: 
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48-0451, eBioscience); 0.125 µg/million cells rat IgG2b Κ, mouse anti-CD3ε PE (CAT#: 
12-0031, eBioscience); 0.125 µg/million cells rat IgG2a Κ, mouse anti-CD8α PE-
Cyanine5.5 (CAT#: 35-0081, eBioscience); 0.125 µg/million cells rat IgG2b Κ, mouse anti-
CD11c Alexa Fluor 488 (CAT#: 53-0144, eBioscience). The following isotype controls were 
used at the same concentration as its corresponding fluorophore conjugated primary 
antibodies: rat IgG2b K isotype control eFluor 450 (CAT#: 48-4031, eBioscience), 
Armenian hamster IgG isotype control PE (CAT#: 12-4888, eBioscience), rat IgG2a K 
isotype control PE-Cyanine5.5 (CAT#: 35–4321, eBioscience), and Armenian hamster IgG 
isotype control Alexa Fluor 488 (CAT#: 53-4888, eBioscience). Monocyte, macrophage, and 
B-cell analysis, was performed using antibodies at the following concentrations: 0.5 µg/
million cells rat IgG2b Κ, mouse anti-CD45 eFluor 450 (CAT#: 48-0451, eBioscience); 0.25 
µg/million cells rat IgG2a mouse anti-CD20PE (CAT#:12-0201, eBioscience), 0.5 µg/
million cells rat IgG2a Κ, mouse anti-F4/80 antigen APC-eFluor 780 (CAT#: 47-4801, 
eBioscience), 10 µL/million cells polyclonal Sheep IgG anti-human/mouse Arginase 1 
Fluorescein-conjugated (CAT#: IC5868F, R&D Systems); 0.06 µg/million cells Rat IgG2a Κ 
mouse anti-NOS2 PE-eFluor 610 (CAT#: 61-5920, eBioscience). The following isotype 
controls were used at the same concentration as its corresponding fluorophore conjugated 
primary antibody: rat IgG2b K Isotype Control eFluor 450 (CAT#: 48-4031, eBioscience), 
rat IgG2a K isotype control PE (CAT#: 12-4321, eBioscience), rat IgG2a K isotype control 
APC-eFluor 780, normal sheep IgG Fluorescein isotype control (CAT#: IC016F, R&D 
Systems), and rat IgG2a K isotype control PE-eFluor 610 (CAT#: 61-4321-82, eBioscience).
3 RESULTS
3.1 T. gondii localizes to the mouse prostate and establishes a chronic infection
To determine if T. gondii establishes a chronic infection (ie, forms bradyzoite tissue cysts) in 
the mouse prostate, male CBA/J mice were injected intraperitoneally with either 40 000 
parasites or sterile PBS for the uninfected controls. This parasite background has been 
engineered to express GFP during the bradyzoite stage (PruΔhxprt + ldh2GFP) to facilitate 
identification of tissue cysts.31 Prostates were assessed for the presence of various parasite-
specific markers at 14 days post infection (DPI), at which time the infection is mostly in the 
acute tachyzoite stage, and at 28 and 60 DPI to monitor chronic infection.29,30 Using 
Western blot GFP was detected in infected mice at all three time points of harvest, but was 
absent in the uninfected controls (Fig. 1A). We next analyzed prostate tissues by 
immunofluorescence assay (IFA) and costained prostates with rhodamine conjugated-
Dolichos biflorus agglutinin (DBA), a lectin that binds terminal α-N-acetylgalactosamine 
residues on the parasite’s tissue cyst wall and GFP.36 Structures exhibiting the characteristic 
staining pattern for tissue cysts were found at each time point (Fig. 1B). To further confirm 
that the GFP/DBA-positive structures in the prostates of infected mice were parasite tissue 
cysts, we co-stained prostate samples with DBA and bradyzoite antigen 1 (BAG1), a 
bradyzoite-specific heat shock protein (Fig. 1C).33 Structures staining with both reagents 
were observed (Fig. 1C), indicating the presence of bradyzoite cysts in the infected prostate 
samples. We did not see DBA staining in uninfected mice, or in prostates of Escherichia coli 
1677 instilled C57/B6 mice, indicating that the presence of DBA staining is specific to T. 
gondii and not a general effect of infection. Collectively, these results indicate that T. gondii 
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chronically encysts in the mouse prostate and can persist in this organ for at least 60 days 
post infection.
3.2 T. gondii infection induces chronic prostatic inflammation
We next sought to determine if T. gondii infection caused inflammation in the mouse 
prostate. We assessed the presence of inflammatory infiltrates in longitudinal sections from 
infected or control prostates at 14, 28, and 60 DPI using hematoxylin and eosin (H&E) stain. 
Infiltrating leukocytes were detected in all samples from infected animals and appeared to be 
significantly increased in numbers compared to uninfected animals (Fig. 2A). To quantitate 
this effect, we used an established scoring system34 that measures inflammatory infiltrate 
based on the intensity, severity and focality. T. gondii induced a significant inflammatory 
reaction in all prostatic lobes at 14 and 28 DPI relative to uninfected age-matched vehicle 
control mice (Fig. 2B). All lobes exhibited similar inflammatory distribution and intensity 
throughout the time course of infection. At 14 DPI each lobe exhibited moderate 
inflammatory infiltrate, however; the dorsal lateral prostate (DLP) lobes exhibited the most 
pronounced time-dependent increase in inflammatory score, progressing from a score of 
5.04 at 14 DPI to a score of 7.17 by 60DPI (Fig. 2B). These data indicate that T. gondii 
infection in the prostate induces chronic inflammation in all lobes of the prostate, which 
increases in severity during persistent infection.
3.3 T. gondii induces a predominantly T-cell immune response in the prostate
As the DLP was found to have the most reproducible and consistent presence of leukocytes 
by H&E staining, we chose this lobe for further characterization of the inflammatory 
response to T. gondii infection of the prostate. We probed for lymphocytic and monocytic 
markers CD20, F4-80, and CD3 by immunofluorescence to identify B lymphocytes, 
monocytes, and lymphocytes, respectively (Fig. 3A). To quantify individual immune cell 
types, we analyzed whole prostates by flow cytometry. As predicted by our 
immunofluorescence assays, there was a significant increase the percent of immune cells as 
a proportion of total live cells (identified by the pan-leukocyte marker, CD45) in infected 
animals relative to vehicle treated control (16.43% infected vs 8% control; P = 0.0026) (Fig. 
3B). This increase is primarily attributed to a significant increase of T-lymphocytes as 
identified by their expression of CD3 (8.2% infected vs 2% control; P = 0.0106) and 
dendritic cells identified as CD11c and CD8α positive (0.48% con vs 1.28% infected vs 
0.48% control; P = 0.0006) (Fig. 3B).
In total, the CD45+ cell population of infected prostates consisted of 49% T-lymphocytes, 
27% monocytes, 16% B cells, and 8% dendritic cells. The CD45+/F4-80+ monocyte 
population consisted primarily of non-polarized monocytes, as 95% failed to express the M1 
marker NOS2 or the M2 marker Arg1. However, of the polarized monocytes, NOS2-
expressing M1 macrophages outnumbered Arg1-expressing M2 macrophages by a 4 to 1 
ratio in infected mice. Collectively, these experiments show that chronic T. gondii infection 
in the prostate elicits a substantial T-cell dominated inflammatory reaction.
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3.4 T. gondii induces reactive epithelial hyperplasia
As inflammatory infiltrate contributes to the release of numerous pro-inflammatory 
cytokines and chemokines that promote the establishment of a reactive microenvironment 
that results in reactive epithelial hyperplasia, we sought to determine if T. gondii infection of 
the prostate results in reactive hyperplasia. Infected and uninfected age-matched control 
prostates were evaluated for epithelial hyperplasia, which is defined as the multi-layering of 
epithelial cell layers and dysplasia of expanded basal or cuboidal cells juxtaposed to 
inflammatory infiltrate (Fig. 4A).37 Significant levels of hyperplasia were detected in all 
sections from infected animals, an observation that was quantified using the scoring system 
described by Boehm et al.34 During acute (14 DPI) and early chronic (28 DPI) T. gondii 
infection, the VP (4.98, 3.94, respectively) and AP (4.62, 3.66, respectively) exhibited a 
substantial hyperplastic response. At 60 DPI, hyperplasia reached a score of 5.78 in the VP 
and 6.73 in the AP. In the DLP, hyperplasia severity increased from 4.27 during acute 
infection, to 6.83 by 60 DPI (Fig. 4B). These findings suggest that T. gondii establishes a 
chronic inflammatory microenvironment, leading to reactive epithelial hyperplasia in all 
lobes of the mouse prostate.
As the DLP exhibited the most reproducible, progressive, and pronounced hyperplastic 
response within the prostate, this lobe was selected for further characterization. To quantify 
epithelial proliferation, control and infected mice were injected with bromodeoxyuridine 
(BrdU) to label replicating cells, and the prostates were harvested 2 h later. We visualized 
BrdU incorporation into replicating DNA by immunofluorescence and found that T. gondii 
infection significantly increased the ratio of proliferating epithelial cells at all time points 
relative to uninfected controls (Fig. 5A,B). These results parallel the histological epithelial 
hyperplasia scores, and further demonstrate that T. gondii-induced inflammation elicits 
reactive hyperplasia. Proliferating cells of the epithelial compartment were confirmed as 
epithelial by pan-cytokeratin staining (Fig. 5A) that clearly demonstrated BrdU+/PanCK+ 
cell populations. The possibility of BrdU+ infiltrating leukocytes was eliminated by co-
staining BrdU with CD45; this experiment failed to show any dual positive cells, (data not 
shown) eliminating inflammatory infiltrate as the potential source of BrdU+ cells.
To determine the lineage of the epithelial cells present in the hyperplastic regions, we probed 
sections from infected and uninfected prostates for markers of basal cells (cytokeratin 5, 
CK5) and luminal cells (cytokeratin 8, CK8).38 Numerous foci of both luminal and basal 
hyperplasia were observed in the hyperplastic regions of infected mice (Fig. 5C). Proposed 
transit amplifying cells (TAC), which express both basal and luminal epithelial cytokeratins 
(CK5 and CK8),39 were prominent in infected prostates but were rarely observed in 
uninfected control mice. These data indicate that TAC populations increase in response to 
infection.
Careful inspection of H&E stained sections revealed a unique histological patterning only 
observed in infected prostates. At 28 DPI we began to observe the formation of small, round, 
and connected glandular structures within the epithelial compartment of inflamed prostates 
(Fig. 6). These small micro-glandular formations remained contained within the basement 
membrane and may maintain their functionality as evidenced by proteinaceous fluid (Fig. 6) 
in their lumens. Additionally, substantial inflammatory infiltrate was commonly juxtaposed 
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to these regions of microglandular hyperplasia. This phenotype was absent in aged-matched 
uninfected mice, and is observed in 13 out of 16 infected prostates at 28 days and is fully 
penetrant at 60 DPI (6/6). These observations indicate that chronic T. gondii infection elicits 
proliferative inflammatory microglandular hyperplasia in the mouse prostate.
4 DISCUSSION
In this study, we show that T. gondii forms bradyzoite tissue cysts in the mouse prostate that 
are associated with the induction of chronic inflammation resulting in reactive hyperplasia. 
The model developed using T. gondii-infected mice should prove useful for the study of 
inflammation-induced hyperplasia of the prostate. In order to characterize the time-course 
and severity of T. gondii-induced prostatic inflammation, we employed the blinded scoring 
system previously reported by Boehm et al.34 In this analysis, we show that T. gondii-
induced inflammation is progressive in severity over time, which was found to be most 
pronounced in the DLP. Our data indicate that the prostatic inflammatory infiltrate are 
primarily T-cells and dendritic cells. These results are in agreement with previous reports of 
the immune response to T. gondii in other organs, such as the brain.40 Toxoplasma is known 
to trigger the expression of dendritic cell-recruiting chemokines, essential in ensuring host 
survival.41 During acute infection, dendritic cells produce IL-12, used in cross-talk with T-
cells signaling them to produce INFɣ. T-cells are necessary for controlling parasite burden 
and enabling host survival during toxoplasmosis.40 T-cells are also implicated in the 
pathology of BPH and are commonly found juxtaposed to hyperplastic regions.37 Future 
studies will be directed at fully characterizing the cytokine component of T. gondii-induced 
inflammation and hyperplasia in the prostate.
T. gondii infection results in the establishment of a chronic reactive inflammatory 
microenvironment in the prostate. During normal repair and recovery homeostatic processes, 
cells will eliminate damage due to noxious stimuli, stimulate epithelial regeneration, and 
stromal remodeling, promote angiogenesis to complete healing, and restore normal tissue 
function. Following these events, inflammation normally subsides.42 However, in cases in 
which the immune system becomes deregulated, or the noxious stimuli or infection persists, 
the inflammation can become chronic by a self-sustaining vicious cycle. T. gondii infection 
induced a reactive microenvironment with substantial proliferation and hyperplasia of both 
luminal and basal epithelial compartments, involving the expansion of transit amplifying 
cells, the proliferative cells implicated in repair and recovery. Inflammation in this model 
resulted in hyperplasia and expansion of the glandular epithelium in a microglandular 
architecture. These microglandular hyperplastic regions exhibit an especially high density of 
BrdU-labeled proliferating cells, and exist in microenvironments that exhibit inflammation. 
This phenotype has never been observed in non-genetically modified or hormone 
manipulated rodents. The only reported example of this atypical hyperplasia has been 
observed for rats treated with exogenous estradiol and testosterone,43,44 suggesting a 
hormonal angle to the mechanism of T. gondii-driven hyperplasia. Finally, it is notable that 
both inflammation and hyperplasia persist and progress at least as long as 60 days in this 
model. It is not clear why inflammation and hyperplasia may worsen at such chronic time 
points, but T. gondii infection typically exhibits recurrent reactivation from its cyst 
(bradyzoite) into its lytic (tachyzoite) life stages. It is possible that this later reactivation of 
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the tachyzoite stage at later time points promotes a continuing of the inflammatory response 
in the prostate. Future studies will be directed at answering this complex question, as well as 
determining how long T. gondii infection persists in the prostate. Infections of greater than 1 
year could be resolved, or could be associated with more severe prostate disease, and or 
future work will answer this critical question.
Based on our results, we propose that T. gondii-infected mice can serve as a powerful new 
model of prostatic inflammation, one that is chronic and does not require the use of 
genetically modified mouse strains. The inflammation induced in this model is similar to 
human inflammation in that the dominant feature is the presence of T-cells and secondary 
macrophages and it slowly builds over time. Several mouse models of prostatic 
inflammation have been developed that have greatly increased our understanding of its 
implication in prostatic disease. Unfortunately, each of the existing models have limitations 
and do not fully recapitulate the human condition. The bacterial strains often used in animal 
models are relatively rarely associated with prostatic infection in the male human 
population.34,45–48 Additionally, some bacterial models require microbial strains which are 
not readily available and/or require laborious culturing conditions. Bacterial models also rely 
on a difficult and potentially damaging instillation techniques of transurethral instillation. 
Importantly, chronic inflammation induced by bacterial models in non-genetically modified 
mice are not fully penetrant, do not affect all lobes, and have not yet been fully characterized 
and quantified. Genetically engineered mice such as the POET-3 autoimmune mouse model 
require particular background strains and back-breeding of protein knockouts onto the 
genetic strain of inflammation, which is costly and time consuming.35,49 Additionally, 
hormone models yield many off-target and systemic effects making data interpretation 
difficult. Finally, each of the models produce variable responses.34,35,46–50
It has become increasingly accepted that inflammation is a causative and driving factor of 
prostate diseases such as BPH and prostate cancer.2,3,6,50 However, the source of 
inflammation has not yet been fully elucidated and the origin of chronic prostatic 
inflammation has proved elusive. There was no precedence in the literature suggesting that 
T. gondii induces prostatic inflammation, however; since T. gondii is a ubiquitous pathogen 
that can persist in a variety of tissues and is associated with chronic inflammation, we 
hypothesized that it could be an inducer of prostatic inflammation relevant to the 
development of human urogenital diseases. Our data support future prospective studies 
involving analysis of T. gondii encystation in the human prostate and serological testing of 
symptomatic BPH patients and those with pathologically confirmed prostate cancer are 
warranted.
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FIGURE 1. 
T. gondii chronically encysts in the mouse prostate. Male CBA/J Mice were injected 
intraperitoneally with either sterile PBS or 40 000 PruΔhpt + ldhGFP T. gondii tachyzoites, 
and euthanized at either 14 (n = 14), 28 (n = 16), or 60 (n = 6) days post infection (DPI), and 
their brains and prostates were collected. (A) T. gondii localization and encystation in the 
mouse prostate was confirmed by detection of T. gondii-expressed GFP by Western blot 
analysis of protein extracts from either uninfected control mice (Con) or infected mice (Inf) 
at the time indicated. (B) T. gondii localization and chronic encystation in the mouse 
prostate was visualized by immunofluorescence in all infected mice prostates at 14, 28, and 
60 DPI. Dorsal lateral prostate (DLP) sections from infected mice for the time indicated 
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were co-stained for T. gondii-expressed GFP (green) and the T. gondii specific cyst wall 
marker Dolichols biflorus agglutinin (DBA) conjugated to rhodamine (red).36 Arrow heads 
denote T. gondii cysts; scale bars mark 25 µm. Serial section of the GFP/DBA stained slides, 
stained with hematoxylin and eosin (H&E). Arrow heads denote T. gondii cysts; scale bars 
mark 25 µm. (C) To confirm specificity of T. gondii labeling, 60 days prostates were co-
stained with bradyzoite antigen (Bag1), the parasite specific heat shock protein, Hsp30 
(green), and DBA (red) and are shown in an 80× image.33 Scale bars represent 25 µm
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FIGURE 2. 
T. gondii infection induces acute and chronic inflammatory responses in the mouse prostate. 
(A) Representative 10× (left) and 40× (right) images of (H&E)-stained sections of dorsal 
lateral prostates (DLP) from uninfected control (left) and T. gondii infected (right) mice at 
14, 28, and 60 DPI Scale bars mark 25 µm. (B) Inflammatory infiltrate scores from DLP, 
ventral (VP), and anterior lobes (AP) of age-matched control and T. gondii infected mice at 
14, 28, and 60 DPI, (n = 6–10, each group) using the established scoring system published 
by Boehm et al.34 Data are presented as the mean inflammatory infiltrate score ± SEM and 
compared to uninfected control mice by two-tailed student’s t-test. *P < 0.05
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FIGURE 3. 
Chronic T. gondii infection of the mouse prostate induces monocytic and lymphocytic 
infiltrate. (A) Representative immunofluorescent images of inflammatory infiltrate in the 
DLP of control (uninfected age-matched) and T. gondii-infected mice at 14 (n = 6), 28 (n = 
10), and 60 (n = 5) DPI stained with the B-cell marker CD20 (top, green), the monocyte 
marker F4-80 (middle, red), and the T-cell marker CD3ε (bottom, red). Scale bars mark 25 
µm. (B) Quantification of immune cells within the CD45+ population by flow cytometry. 
Data shown are the ratio of total inflammatory cells to total live cells (whole bar length), and 
the ratio to total live cells of CD3ε+ T lymphocytes (black portion of the bar), CD20+ B 
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lymphocytes (grey portion), F4-80+ monocytes (hatched portion), and Cd11c+/CD8α+ 
dendritic cells (white portion) in T. gondii-infected and age-matched control mice at 28 DPI. 
Data are presented as mean ratio to total live cells ± SEM; infected and control groups were 
compared by two-tailed student’s t-test. *P < 0.05 (n = 6)
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FIGURE 4. 
Prostatic inflammation induced by T. gondii results in reactive hyperplasia. (A) 
Representative 20× (left) and 40× (right) images of H&E-stained DLPs from uninfected 
control (left) and T. gondii-infected (right) mice at 14, 28, and 60 DPI. Scale bars mark 25 
µm. (B) Hyperplasia scores from DLP, VP, and AP of age-matched-control and T. gondii-
infected mice at 14, 28, and 60 DPI (n = 6–10, each group) using the scoring system 
established by Boehm et al.34 Data are presented as the mean hyperplasia score ± SEM. 
Infected mice are compared to uninfected control mice by two-tailed student’s t-test. *P < 
0.05
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FIGURE 5. 
T. gondii-induced reactive hyperplasia exhibits epithelial proliferation, expansion of transit 
amplifying cells, and proliferative microglandular hyperplasia in chronically infected 
prostates. Proliferation in T. gondii-infected and control mice was determined by BrdU-
labeling 2 h prior to sacrifice followed by immunofluorescence. (A) Representative BrdU 
staining at 28 DPI. BrdU (green), pan-cytokeratin (red), scale bars indicate 25 µm. (B) 
Quantified data of BrdU-positive epithelial cells from infected and control prostates 
harvested at 14 (n = 6), 28 (n = 6), and 60 (n = 4) DPI. Three random 20× views/mouse 
prostate were quantified and averaged as percent proliferating (BrdU+) epithelial cells to 
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total epithelial cells in the field of view. Data are presented as the mean % BrdU+ epithelial 
cells ± SEM in each group. Infected mice are compared to age-matched control by two-
tailed student t-test; *P < 0.05. (C) Expansion of epithelial transit amplifying cells (TACs) 
determined by cytokeratin 5 and 8 co-immunofluorescent staining. Representative T. gondii-
infected 28 and 60 days mouse prostates immunostained with the basal epithelial marker 
cytokeratin 5 (CK5) (red) and luminal epithelial marker cytokeratin 8 (CK8) (green), as 
indicated by arrow heads. Scale bars represent 25 µm
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FIGURE 6. 
Chronic T. gondii infection elicits proliferative inflammatory reactive microglandular 
hyperplasia in the mouse prostate at 28 (top) and 60 DPI (bottom). This phenotype is 
observed in 13/16 prostates at 28 DPI and is fully penetrant at 60 DPI (n = 6)
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